(Buzz from a blog titled:" biopharmaceutical Industry intelligence and analysis blog" Note the info concerning new delivery system utilizing a "pressurized infustion to deliver drugs to the brain")

http://invivoblog.blogspot.com/2010/...-to-stars.html

--"Amgen/Biovail/MedGenesis: Since its annus horribilis... 2007, Amgen has been more willing to share.. the once-voracious acquirer is now... an out-licenser, and this week it sent exclusive global rights to glial cell line-derived neurotrophic factor (GDNF) ...to Canadian firms MedGenesis Therapeutix and Biovail. Terms weren't disclosed other than Amgen taking what the firms described as a "small equity stake" in MedGenesis. Near-term, the three-sided deal allows Biovail and MedGenesis to team up and develop GDNF for Parkinson's disease using MedGenesis delivery technology. MedGenesis said it also has taken rights to GDNF for non-CNS indications and could collaborate with other partners. The Vancouver firm is applying its platform of convection enhanced delivery, which uses pressurized infusion to deliver drugs locally to the brain, to treat epilepsy and glioblastoma multiforme. -- Alex Lash"

Could it be Amgen is willing to "share" license to GDNF because MedGenesis or Biovail have developed a new delivery system, thus letting Amgen off the hook? Should the new clinical trials prove positive, Amgen can claim "oh look, the new delivery system made all the difference.."